There are clinical trials studying these novel inhibitors, such as a recent phase I/II study, that demonstrated the safety and efficacy of entospletinib (SYK inhibitor) in combination with obinutuzumab in relapsed/refractory (r/r) CLL[52] or an ongoing phase I study of a novel MALT inhibitor JNJ067856633 in r/r CLL and non-Hodgkin lymphoma (NHL). The gene discussed is SYK; the disease is non-Hodgkin lymphoma.